Hematopoietic cell infusion for the treatment of nuclear disaster victims: New data from the Chernobyl accident
Sergiy Klymenko, Nelson J. Chao(Duke University), Kovalenko An(Institute of Clinical Research), Joel Ross(The University of Texas Southwestern Medical Center), Janna N Minchenko(Institute of Clinical Research), Zhiguo Li(Harbin Medical University), Jiang Chen(Duke University), Д А Белый(Institute of Clinical Research), Volodymyr Bebeshko(Institute of Clinical Research), Kouros Owzar(Duke University)
Cited by 15
Related Papers
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
|The Lancet|2009|1.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2020|739
Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
|Journal of Clinical Oncology|2008|655
Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research
|Biology of Blood and Marrow Transplantation|2014|442